SK pharmteco Names Andrew Fenny Chief Commercial Officer

September 27, 2023


RANCHO CORDOVA, Ca. (September 27, 2023) – SK pharmteco, a global contract development and manufacturing organization serving the pharmaceutical industry, today announced Andrew (Andy) Fenny as Chief Commercial Officer. In this newly created role, Fenny will shape customer-focused strategies and be responsible for SK pharmteco’s sales and marketing initiatives and execution.

“I am thrilled to have Andy joining us as our Chief Commercial Officer,” said Joerg Ahlgrimm, CEO of SK pharmteco. “Under Andy’s leadership, we will keep driving value for our clients by developing innovative solutions that support their commitments to bring new therapies to market and to consistently provide lifesaving therapies to patients.”

Fenny brings more than 20 years of experience in the Life Sciences industry, most recently serving as the Chief Business Officer at FUJIFILM Diosynth Biotechnologies (FDB). At FDB, Andy was responsible for commercial development, global alliance management, marketing and communications, strategic business development, enterprise business planning, and functions.

Prior to the acquisition of the CDMO business by FUJIFILM from MSD, Fenny served as Senior Programme Manager at both MSD and Avecia in the United Kingdom.

“SK Pharmteco is entering a period of exceptional growth and I am excited to serve as a member of the leadership team to take us to the next level,” said Fenny. “Our vision is to be the most trusted partner in the manufacture and testing of medicines, and through this, benefit patients and society worldwide.”

Originally from the U.K., Fenny now calls Apex, N.C. home with his wife Janine and children, Peyton (12) and Hayden (11).


About SK pharmteco
Headquartered in Rancho Cordova, Calif., SK pharmteco is a global contract development and manufacturing organization specializing in the production of active pharmaceutical ingredients (APIs), advanced intermediates, and cell and gene therapy for the pharmaceutical industry. SK pharmteco is comprised of six companies: SK Biotek Korea, SK Biotek Ireland, AMPAC Fine Chemicals, AMPAC Analytical Laboratories in the U.S., Yposkesi and the Center for Breakthrough Medicines. SK pharmteco is owned by SK Inc., the strategic investment arm of South Korea’s SK Group. For more on SK pharmteco, visit

Keith Bowermaster, APR, CCMP

SOURCE: SK pharmteco

Scroll to Top

Enter your details to access Marketing Materials